Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.
- June 2026 — CDMO Opportunities And Threats Report
- The Decision Rights Matrix: Making Sponsor-CDMO Governance Enforceable
- Defining Quality In A Sponsor-Owned QTPP Before The CDMO Even Starts
- ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive Malignancies
- Reshoring Pressure Meets Manufacturing Reality
- CDMO Live Europe 2026: Partnerships For An Uncertain World
- Resilience, Risk, And Relationships: CDMO Live Europe 2026 Report
- Demonstrating Non-Inferiority Of BFPCs Vs. Traditional Air Monitoring
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Native RPLC For ADCs: How Column Hydrophobicity Shapes DAR Separation
ADC characterization does not have to be overwhelmed by complex intact MS profiles. Smart column selection can improve separation, clarify critical quality attributes, and make ADC analysis easier.
-
Organ-On-A-Chip Technology Unlocks Patient-Derived Precision Medicine
Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.
-
Evaluating The Expression Patterns Of Multiple Inhibitory Receptors
Discover how an innovative approach to interpreting T-cell exhaustion and inhibitory receptor expression is paving the way for innovative therapeutic approaches aimed at rejuvenating T-cell function.
-
Viral Disinfectant Efficacy Studies: Key Guiding Factors And Design Elements
Achieving compliance and safety through Disinfectant Efficacy Studies (DES) is about adhering to regulations and committing to high standards of safety and quality of manufacturing operations.
-
Handle Your Large-Scale Buffer Preparation Efficiently
Discover how to prepare 10x PBS using an innovative system to ensure scalable, efficient, and consistent buffer preparation for large-scale workflows.
-
Highly Sensitive ELISAs In 90 Minutes
Traditional ELISA methods are often limited by their relatively low throughput and need for multiple wash steps. Learn about a solution that overcomes these challenges and provides rapid results.
-
Comparison Of Different Methods To Isolate HMW DNA From Bacteria
Different extraction methods produce dramatically different DNA sizes and qualities, directly affecting long‑read sequencing results. See how performing early QC can improve sequencing success.
-
A Scalable Manufacturing Platform For The Purification Of Stem Cell Derived Exosomes
EV production scale increases require paired robust, scalable, and cost-effective downstream processes. Process parameters can be tailored for therapeutic exosome programs and allow for maximum exosome recovery.
-
Monitoring Of A pH Optimization Approach For CHO Cell Cultivation
Cloud-based monitoring and analytics help centralize data, gain real-time insight, and improve decision-making. Enhanced visibility and collaboration enable faster optimization and consistency across development and manufacturing.
-
Quality Control In IVT RNA Workflow
Accurate sizing and purity checks are essential in IVT RNA workflows. Explore how automated electrophoresis improves QC efficiency and ensures RNA integrity for downstream applications.
NEWSLETTER ARCHIVE
- 08.07.26 -- New Podcast Episodes: BoB@BIO, In Vivo Gene Editing, Multispecific Manufacturability, and More
- 08.07.26 -- Inside ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive T-Cell Malignancies
- 08.06.26 -- The CDMO Perspective On Breaking Down Development Silos In Vivo CGT
- 08.05.26 -- Advancing Precision In Clinical Trial Design
- 08.05.26 -- How Precision Oncology Is Redefining Cancer Drug Development With Aprea Therapeutics' Dr. Oren Gilad
- Solving Vector Yield Challenges Starts Long Before Manufacturing
- Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors
- FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy
- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale
- In Vivo Gene Editing Is Moving From Promise To Proof
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections